Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

167.38 -0.17 (-0.10%)

Streaming Delayed Price Updated: 12:41 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

56 57 Next >

Eli Lilly Leads 5 Stocks To Watch In Bear Market ↗

October 08, 2022

Eli Lilly is holding up, while others crumbled Friday amid the market sell-off.

Via Investor's Business Daily

MarketBeat: Week in Review 10/3-10/7

October 08, 2022

The jobs report is fueling a sell-off to end the week with more volatility on tap for next week. Here are some of the most popular articles from this week.

Via MarketBeat

Topics Economy Electric Vehicles

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022 ↗

October 07, 2022

Upgrades

Via Benzinga

Is This Stock a Buy After Soaring by 37%? ↗

October 06, 2022

Don't press the buy button too fast.

Via The Motley Fool

One Of Eli Lilly's Most Anticipated Drugs Could Hit The Market Next Year ↗

October 06, 2022

The Street is closely watching Lilly's efforts in obesity and Alzheimer's.

Via Investor's Business Daily

3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up

October 06, 2022

Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates

Via MarketBeat

Should You Sell Your FANGMAN Stocks? ↗

October 05, 2022

In addition to energy, investors have been fleeing to healthcare stocks for safety. And they have been selling the big tech names, especially the semiconductors.

Via Talk Markets

Hey Biogen Investors, Don’t Chase BIIB Stock! ↗

October 05, 2022

If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside.

Via InvestorPlace

Will Investors Notice Exciting Sign On Biogen's Chart? ↗

October 05, 2022

If history is any guide, there may be good fortune ahead for shares of Biogen (NASDAQ:BIIB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...

Via Benzinga

2 Signals to Watch Before Buying SAVA Stock ↗

October 05, 2022

SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play.

Via InvestorPlace

Peering Into Biogen's Recent Short Interest ↗

October 04, 2022

Biogen's (NASDAQ:BIIB) short percent of float has risen 9.52% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 1.61% of all regular shares that...

Via Benzinga

Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System ↗

October 04, 2022

Biotechnology companies such as Biogen Inc. (NASDAQ: BIIB), Alector Inc.

Via Benzinga

Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio ↗

October 03, 2022

Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.

Via Talk Markets

US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent ↗

October 03, 2022

The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera.

Via Benzinga

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

October 03, 2022

From Denali Therapeutics Inc.

Via GlobeNewswire

Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗

September 30, 2022

The major indexes fell, with the S&P 500 breaking below bear market lows.

Via Investor's Business Daily

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

September 30, 2022

From Biogen Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

September 29, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗

September 29, 2022

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...

Via Benzinga

Netflix, Biogen And Other Big Gainers From Wednesday ↗

September 29, 2022

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

7 Growth Stocks to Buy to Tap Into a Hidden Bull Market ↗

September 28, 2022

It's become a bit easier for investors to find growth stocks to buy hidden amid the bear market.

Via InvestorPlace

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗

September 28, 2022

Via Benzinga

Here's How Much $100 Invested In Biogen 20 Years Ago Would Be Worth Today ↗

September 28, 2022

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.9% on an annualized basis producing an average annual return of 10.93%. Currently, Biogen has a market capitalization of...

Via Benzinga

Alphabet To $136? Plus This Analyst Slashes PT On United Natural Foods ↗

September 28, 2022

Truist Securities cut the price target on Alphabet Inc. (NASDAQ: GOOGL) from $145 to $136. Truist Securities analyst Youssef Squali maintained a Buy rating on the stock. Alphabet shares rose 2.5% to...

Via Benzinga

What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data ↗

September 28, 2022

Going back to at least December 2014, Biogen Inc (NASDAQ: BIIB) has been diligently working on drugs to cure Alzheimer's disease. Both the negative and positive data revealed over the years have...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 28, 2022

Gainers

Via Benzinga

Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results ↗

September 28, 2022

Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring.

Via InvestorPlace

Why Is Prothena (PRTA) Stock Up 75% Today? ↗

September 28, 2022

Prothena (PRTA) stock is seeing massive gains on Wednesday despite a lack of recent news from the late-stage clinical company.

Via InvestorPlace

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗

September 28, 2022

Gainers

Via Benzinga

Why Is Acumen (ABOS) Stock Up 95% Today? ↗

September 28, 2022

Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company.

Via InvestorPlace

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Starting at $3.75/week.

Subscribe Today